Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

abrocitinib had a significantly higher drug survival rate compared to dupilumab when treating patients with atopic dermatitis. Although, the authors note, there are certain benefits to choosing ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab ...